Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics Inc (GLUE) Implied Volatility Current
GLUE implied volatility is 147%. IV Rank is 83%, placing current premiums in the top of their 52-week range.
Read more
Tracking GLUE implied volatility helps you identify when options premiums on Monte Rosa Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Monte Rosa Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when GLUE IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Monte Rosa Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.
Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For GLUE, tracking metrics like GLUE IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on GLUE signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies.
Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where GLUE implied volatility sits today versus where it has been. Our scanner ranks Monte Rosa Therapeutics Inc implied volatility against its historical range, surfaces extremes in GLUE IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Monte Rosa Therapeutics Inc IV is rich or cheap — measure it, then act on it.
Implied Volatility
IV is near its yearly peak - premiums are expensive, favoring sellers.
As of September 23, 2026
Trade options with IV on your side
Track GLUE IV rank across every expiration, spot where volatility is elevated, and identify high-probability setups before the window closes.
Start your 14-day free trial→